Market research
CGS.AU Cogstate Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 594M
- P/E ratio
- 34.5
- Analyst target
- 4.3123
- Dividend yield
- 0.8%
- Beta
- 0.27
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU000000CGS8
- Market cap
- 594M
- P/E ratio
- 34.5
- Analyst target
- 4.3123
- Dividend yield
- 0.8%
- Beta
- 0.27
About
About Cogstate Limited
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CGS.AU discussion.
5 years, 6 months ago
Cogstate Limited is currently in a long term uptrend where the price is trading 35.0% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Cogstate Limited's total revenue rose by 42.9% to $14M since the same quarter in the previous year.
Its net income has increased by 78.3% to $-448K since the same quarter in the previous year.
Finally, its free cash flow grew by 449.7% to $7M since the same quarter in the previous year.
Based on the above factors, Cogstate Limited gets an overall score of 5/5.